7JN Stock Overview
Operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Poolbeg Pharma PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.064 |
| 52 Week High | UK£0.17 |
| 52 Week Low | UK£0.037 |
| Beta | 2.14 |
| 1 Month Change | -14.77% |
| 3 Month Change | -27.84% |
| 1 Year Change | -37.75% |
| 3 Year Change | -30.98% |
| 5 Year Change | n/a |
| Change since IPO | -31.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7JN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -15.9% | 2.3% | 1.4% |
| 1Y | -37.7% | -14.5% | 9.1% |
Return vs Industry: 7JN underperformed the German Pharmaceuticals industry which returned -14.5% over the past year.
Return vs Market: 7JN underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| 7JN volatility | |
|---|---|
| 7JN Average Weekly Movement | 28.0% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7JN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7JN's weekly volatility has increased from 16% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 15 | Jeremy Skillington | www.poolbegpharma.com |
Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Poolbeg Pharma PLC Fundamentals Summary
| 7JN fundamental statistics | |
|---|---|
| Market cap | €27.12m |
| Earnings (TTM) | -€5.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.1x
P/E RatioIs 7JN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7JN income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£4.38m |
| Earnings | -UK£4.38m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0088 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7JN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 03:17 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Poolbeg Pharma PLC is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adam McCarter | Cavendish |
| Brian White | Shore Capital Group Ltd |